TEVA-CAPTOPRIL 50 MG
CAPTOPRIL : 50 MG · DIN 01942980 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-CAPTOPRIL?
TEVA-CAPTOPRIL 50 MG contains CAPTOPRIL : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 01942980, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Jul-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is TEVA-CAPTOPRIL called?
The same molecule, CAPTOPRIL, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CAPTOPRIL | Latin | Brazil, Lebanon |
| CAPTOLAB | Latin | Brazil |
| Acetab | Latin | Bahrain, Saudi Arabia |
| Capoten | Latin | Australia, South Africa |
| CAPOX | Latin | Brazil |
| CAPTOCORD | Latin | Brazil |
| CAPEN | Latin | Morocco |
| CAPTOSEN | Latin | Brazil |
| CONVERTAL | Latin | Morocco |
| HIPOTENSIL | Latin | Morocco |
| LOPRIL | Latin | Morocco |
| Capace | Latin | South Africa |
| Capozide | Latin | South Africa |
| CAPOZIDE TABLET | Latin | Saudi Arabia |
| CaptoHexal | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 01942980 |
|---|---|
| Brand name | TEVA-CAPTOPRIL |
| Generic / active ingredient | CAPTOPRIL : 50 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA01 CAPTOPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Jul-2011 |
| Original market date | 1991-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 01942980 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1942980 |
| Brand name | TEVA-CAPTOPRIL |
| Active ingredient / INN | CAPTOPRIL : 50 MG |
| ATC code | C09AA01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09 |
| AHFS class | 24:32.04 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
Which pack is which?
| Strength on the label | 50 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code C09AA01 CAPTOPRIL. 9 of 77 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CAPTO TAB 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00893625 |
| APO-CAPTO TAB 12.5MG | 12.5 MG | TABLET | APOTEX INC | MARKETED | DIN 00893595 |
| APO-CAPTO TAB 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 00893617 |
| NOYADA | 25 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543915 |
| NOYADA | 5 MG / 5 ML | SOLUTION | ETHYPHARM INC | MARKETED | DIN 02543907 |
| TEVA-CAPTOPRIL | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942999 |
| TEVA-CAPTOPRIL | 12.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942964 |
| TEVA-CAPTOPRIL | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01942972 |
| APO-CAPTO TAB 25MG | 25 MG | TABLET | APOTEX INC | DORMANT | DIN 00893609 |
| APO-CAPTO TAB 6.25MG | 6.25 MG | TABLET | APOTEX INC | DORMANT | DIN 01999559 |
Who else supplies CAPTOPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAPTOPRIL appears in 134 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CAPTOPRIL cost around the world?
CAPTOPRIL is listed on 14 national price registers Nexara tracks, across 213 pack listings published on 13 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Brazil | preco fabrica (ex-factory ceiling) | 10 | 74 | 02 Sep 2026 |
| United States | acquisition | 4 | 50 | 03 Sep 2026 |
| South Africa | single exit price | 17 | 18 | 01 Sep 2026 |
| Saudi Arabia | public | 17 | 17 | 01 Sep 2026 |
| Romania | max producer price | 14 | 15 | 03 Sep 2026 |
| Spain | PVP con IVA (public price) | 8 | 8 | 05 Sep 2026 |
| Morocco | PPV (public price) | 4 | 8 | 05 Sep 2026 |
| Bahrain | retail (max) | 2 | 6 | 01 Sep 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Italy | prezzo al pubblico (classe A) | 3 | 5 | 02 Sep 2026 |
| United Arab Emirates | public | 2 | 3 | 31 Aug 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | 02 Sep 2026 |
| Australia | ex-manufacturer | 1 | 1 | 08 Sep 2026 |
| Greece | producer price (ex-factory) | 1 | 1 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.